SK life science

Understanding Lennox-Gastaut Syndrome

Lennox-Gastaut Syndrome (LGS) is a severe and rare form of childhood-onset epilepsy.[1] There are four key components to a LGS diagnosis:

1. Seizures that begin in early childhood[2]
2. More than one seizure type that continues despite treatment[2]
3. Abnormal brain waves on an electroencephalogram (EEG) test[2]
4. Developmental delays and/or intellectual disabilities[2]

What Are Seizures?

A seizure is a sudden surge of electrical activity in the brain caused by complex chemical changes that occur in nerve cells.[3]

Usually, there is a balance of cells that either encourage or stop other brain cells from sending messages. A seizure occurs when there may be too much or too little electrical activity in the brain causing an imbalance.[3]

Seizures are a symptom of many different disorders that can affect the brain.[3]

Lennox-Gastaut Syndrome
By the Numbers

LGS IMPACTS:

1-2% of people with epilepsy[4]	**48,000** children and adults in the U.S.[4]
3-4% of children with epilepsy[4]	**1 MILLION** children and adults worldwide[4]

What Causes LGS?

LGS develops when the brain is affected at a critical time in its development. Causes can include brain injury before or during birth, abnormal brain formation, infections, genetic factors, metabolic disorders, seizures as an infant, head injury and autoimmune disorders.[5]

In about 30% of cases, the cause of LGS is unknown.[5]

Current Unmet Need

There is no cure for LGS. The priority for patients with LGS is seizure management, through options such as anti-seizure medications, specialized diets, brain surgery and neurostimulation.[1] Despite the best treatment plans, more than 85% of children with LGS will continue to have seizures into adulthood, and more than 90% have significant intellectual disabilities.[1]

Our Commitment to LGS

At SK life science, we are committed to applying our expertise in the brain and its underlying biology to develop new therapy options for central nervous system (CNS) disorders, including LGS.

LGS is very difficult to treat. As a company, we prioritize developing treatments in areas of significant unmet need, where our R&D expertise can have the most impact. Notably, we have initiated a Phase 3 trial to evaluate our compound, carisbamate, as a potential treatment for LGS.

We continue to listen to the needs of patients, caregivers, HCPs and scientists to help guide us in developing new compounds, and we support advocacy and community programs to help change what's possible in CNS treatment.

Please always consult a doctor with any questions.

For additional information, please visit: www.sklifesciencesinc.com

Media Inquiries: media@SKLSI.com

Follow Us

@SKlifescience

SK Life Science, Inc.

1 LGS Foundation. What is Lennox-Gastaut Syndrome? https://www.lgsfoundation.org/about-lgs-2/what-is-lennox-gastaut-syndrome/
2 LGS Foundation. How is LGS Diagnosed? https://www.lgsfoundation.org/about-lgs-2/how-is-lgs-diagnosed/
3 Epilepsy Foundation. What is a Seizure? https://www.epilepsy.com/learn/about-epilepsy-basics/what-seizure
4 LGS Foundation. LGS Fact Sheet. https://www.lgsfoundation.org/wp-content/uploads/2021/05/LGSF-Fact-Sheet-2021.pdf
5 LGS Foundation. What Causes LGS? https://www.lgsfoundation.org/about-lgs-2/what-causes-lgs/

NP-US-CA-0001